NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
Stifel Nicolaus Sticks to Its Buy Rating for Cipher Pharmaceuticals (CPHRF)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...
Stifel Nicolaus Keeps Their Buy Rating on Savaria (SIS)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS – Research Report) today and set a price target of ...
Yahoo Finance15d
NervGen Pharma Corp (9UA.SG)
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...
GMA Network19d
Tropical Storm Enteng: A list of Metro Manila malls offering free parking, WiFi, charging stations
Since Sunday, Tropical Storm Enteng (international name: Yagi) has brought rains and caused heavy flooding in Metro Manila and its neighboring cities, with Signal No. 2 raised in nine areas in Luzon.
Pharmaceutical Technology25d
NVG-291 by NervGen Pharma for Spinal Cord Injury: Likelihood of Approval
NVG-291 is under clinical development by NervGen Pharma and currently in Phase II for Spinal Cord Injury. According to GlobalData, Phase II drugs for Spinal Cord Injury does not have sufficient ...
The Globe and Mail25d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions ...
Nasdaq26d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...
kalkinemedia26d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated t... "Lorem ipsum dolor sit amet, ...
Stockhouse26d
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...